Apparently, on the back of strong marketing push, Pfizer has logged a 6.6% topline growth in 1QFY03. The growth has been marginally better than our expectations. The highlight of the results was a sharp improvement in operating margins compared to the last year by more than 570 basis points.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share
P/E (at current price)
*- 1QFY03- is for the quarter ending Feb'02.
The boost in sales and operating margins seem to be on the back two main reasons. One, the company's 'Corex' range of cough preparations which contribute around 30% of the company’s sales are logging 8%-9% growth rates. Further, inspite of strong competition new products like Magnex and Hepashield are selling at a premium.
At the current market price of Rs 446, the stock is trading at 22x FY03 expected earnings. The company is expected to be a major beneficiary of the recent DPCO dilution. Becosules, Pfizer's top selling brand is expected to come out of price control. Becosules enjoys a market share of around 25% in the Vitamin B market with a strong brand recall and one can expect a ramp up in margins if the product actually comes out of price control.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407